ARTICLE | Product Development
ImaginAb, pharmas in precompetitive push for T cell imaging biomarker
ImaginAb rallies pharmas to develop shared understanding of its T cell imaging biomarker
October 15, 2019 8:32 PM UTC
Updated on Oct 18, 2019 at 2:08 AM UTC
ImaginAb’s pharma collaboration to develop its CD8+ T cell PET imaging agent is the latest indicator that the best way to develop biomarkers for immuno-oncology is by committee.
On Monday, ImaginAb Inc. announced an up to three-year collaboration with AstraZeneca plc (LSE:AZN; NYSE:AZN), Pfizer Inc. (NYSE:PFE) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to establish proof of concept and best practices for its CD8 ImmunoPET technology. ...